Phenotypes Associated with This Genotype

Genotype
MGI:5639318

• Allelic Composition: Picalm^tm1.1Tmae/Picalm^tm1.1Tmae; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

enlarged spleen ( J:220728 )

hypochromic microcytic anemia ( J:220728 )

• mice develop microcytic and hypochromic anemia following polyinosinicpolycytidylic acid (pIpC) treatment

impaired hematopoiesis ( J:220728 )

decreased erythroblast number ( J:220728 )

• decreased number of mature (R4) erythroblasts in the spleen in proportion to number of R2 erythroblasts

increased erythroblast number ( J:220728 )

• increased numbers of immature (R2) erythroblasts in the spleen in proportion to number of R4 erythroblasts

abnormal erythrocyte morphology ( J:220728 )

• variation in red blood cell size and shape

abnormal erythropoiesis ( J:220728 )

• impaired transition of stage III (poly-chromatophilic) to stage IV (ortho-chromatophilic) erythroblasts

• increase in erythroblast apoptosis

• decrease in number of fully-formed clathrin coated pits in erythroblast

decreased erythrocyte cell number ( J:220728 )

• reduced numbers of red blood cells in peripheral blood following pIpC treatment

decreased hematocrit ( J:220728 )

• reduced hematocrit levels in peripheral blood following pIpC treatment

decreased hemoglobin content ( J:220728 )

• reduced hemoglobin levels in peripheral blood following pIpC treatment

• reticulocytes have a low hemoglobin content

decreased mean corpuscular hemoglobin ( J:220728 )

• decreased mean corpuscular volume following pIpC treatment

decreased mean corpuscular volume ( J:220728 )

• decreased mean corpuscular hemoglobin following pIpC treatment

increased red blood cell distribution width ( J:220728 )

• increased red cell distribution width in peripheral blood following pIpC treatment

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells beginning 3 months after pIpC treatment

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells beginning 5 months after pIpC treatment

reticulocytosis ( J:220728 )

• elevated reticulocyte counts

• increase in percentage of immature reticulocyte fraction

homeostasis/metabolism

increased circulating erythropoietin level ( J:220728 )

• high serum erythropoietin levels beginning 2 months after pIpC treatment

abnormal iron homeostasis ( J:220728 )

• increased amounts of surface-bound transferrin in relation to internalized transferrin on erythroblasts as compaired to wild-type

• transferrin receptor endocytosis is 25% as efficient as wild-type

increased circulating iron level ( J:220728 )

• elevated serum iron levels

immune system

enlarged spleen ( J:220728 )

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells beginning 3 months after pIpC treatment

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells beginning 5 months after pIpC treatment

growth/size/body

enlarged spleen ( J:220728 )